AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19652123 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 259
Study 17449082 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density EEG investigation of cortical processing of a rotating visual pattern
Number of subjects: 4
Study 16785332 — intervention group
Group type: EXPERIMENTAL
Intervention: Water (H2O)
Number of subjects: 9
Study 16785332 — intervention group
Group type: COMPARATOR
Intervention: Salt water (NaCl-H2O)
Number of subjects: 9
Study 15577460 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly cross‐linked polyethylene
Number of subjects: 92
Study 15577460 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 92
Study 11246648 — intervention group
Group type: EXPERIMENTAL
Intervention: Support program for caregivers of dementia patients
Number of subjects: 49
Study 8971314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol elixir 40 mg/kg preoperatively (Group A)
Number of subjects: 100
Study 8971314 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol suppositories 40 mg/kg after induction of anaesthesia (Group B)
Number of subjects: 100
Study 8971314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol elixir (Group A)
Number of subjects: 100
Study 8971314 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol suppositories (Group B)
Number of subjects: 100
Study 8971314 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 8971314 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with plasma paracetamol concentrations above 0.07 mmol/l
Number of subjects: 100
Study 1281078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheek electrodes
Number of subjects: 22
Study 1281078 — intervention group
Group type: COMPARATOR
Intervention: Sphenoidal electrodes
Number of subjects: 22
Study 3883968 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon‐aminocaproic acid
Number of subjects: 96
Study 3883968 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 96
Study 30958329 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck stabilization exercise and breathing retraining exercise (15 minutes each) in addition to rehabilitation exercise treatment.
Number of subjects: 30
Study 30958329 — intervention group
Group type: COMPARATOR
Intervention: Breathing retraining exercise (30 minutes) in addition to rehabilitation exercise treatment.
Number of subjects: 30
Study 27777235 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (as selenomethionine)
Number of subjects: 6546
Study 27777235 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (as α‐tocopherol)
Number of subjects: 6546
Study 27777235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6546
Study 25873045 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus Fuzheng Kang'ai decoction (FZKA)
Number of subjects: 70
Study 25873045 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib plus placebo
Number of subjects: 70
Study 24063435 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Community Health Worker (CHW)‐provided home visits
Number of subjects: 140
Study 24063435 — intervention group
Group type: COMPARATOR
Intervention: Standard care received through the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) office visits
Number of subjects: 140
Study 21048039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus platinum/5‐fluorouracil (5‐FU)
Number of subjects: 442
Study 21048039 — intervention group
Group type: COMPARATOR
Intervention: Platinum/5‐fluorouracil (5‐FU) alone
Number of subjects: 442
Study 19766902 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (5mg daily for 8 weeks)
Number of subjects: 40
Study 19766902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18044061 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic bronchodilator
Number of subjects: 0
Study 18044061 — intervention group
Group type: COMPARATOR
Intervention: β-agonist bronchodilator
Number of subjects: 0
Study 18044061 — intervention group
Group type: COMPARATOR
Intervention: Comparison of β-agonists and anticholinergics
Number of subjects: 0
Study 18044061 — intervention group
Group type: COMPARATOR
Intervention: β-agonists added to anticholinergic or inhaled corticosteroid use
Number of subjects: 0
Study 15110023 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 100 mg
Number of subjects: 8
Study 15110023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11136927 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 18
Study 11136927 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 18
Study 11136927 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with preserved autoregulation
Number of subjects: 18
Study 9389815 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 0
Study 9389815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7950288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (6 x 50 mg Fe2+ aspartate/day)
Number of subjects: 60
Study 7950288 — intervention group
Group type: COMPARATOR
Intervention: Parenteral iron therapy (0.75 mg/kg BW complex‐bound Fe3+ once a week by infusion)
Number of subjects: 60
Study 2891224 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg once at night
Number of subjects: 48
Study 2891224 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 20 mg bid
Number of subjects: 48
Study 2891224 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg bid
Number of subjects: 48
Study 2891224 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg bid
Number of subjects: 48
Study 31420120 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin for 21 consecutive days
Number of subjects: 30
Study 31013189 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC-related infection (CRI) group
Number of subjects: 100
Study 31013189 — intervention group
Group type: COMPARATOR
Intervention: Non-CRI group
Number of subjects: 100
Study 31013189 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC duration in CRI group
Number of subjects: 100
Study 31013189 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hospital length of stay (LOS) in CRI group
Number of subjects: 100
Study 31013189 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual CRI rates
Number of subjects: 100
Study 28610880 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscope-Assisted TAP (LTAP) block
Number of subjects: 80
Study 28610880 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-Guided TAP (UTAP) block
Number of subjects: 80
Study 25205008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia plus treatment as usual (TAU)
Number of subjects: 37
Study 25205008 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 37
Study 22476926 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Number of subjects: 10
Study 22476926 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion
Number of subjects: 10
Study 22476926 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 10
Study 21272713 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscular training (IMT)
Number of subjects: 21
Study 21272713 — intervention group
Group type: COMPARATOR
Intervention: Control group (no threshold resistance valve)
Number of subjects: 21
Study 19861886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of the distal vein in AVF
Number of subjects: 60
Study 19861886 — intervention group
Group type: COMPARATOR
Intervention: Non-ligated group
Number of subjects: 60
Study 19861886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16505644 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine dipeptide (0.5 g.kg‐1.day‐1; Ala‐Gln group, n=58)
Number of subjects: 114
Study 16505644 — intervention group
Group type: COMPARATOR
Intervention: L-alanine+L-proline (control group, n=56)
Number of subjects: 114
Study 15008374 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional geometrical characterization of aneurysm sac using indices such as maximum diameter, neck diameter, height, aspect ratio, bottleneck factor, bulge location, volume, surface area, Gaussian and mean curvatures, isoperimetric ratio, and convexity ratio.
Number of subjects: 9
Study 15008374 — intervention group
Group type: COMPARATOR
Intervention: Size-matched hypothetical control aneurysms.
Number of subjects: 9
Study 14768792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mega-dose methylprednisolone (MDMP) 30 mg/kg/d for 3 days and 20 mg/kg/d for 4 days
Number of subjects: 42
Study 14768792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg/d for 2 days
Number of subjects: 42
Study 14768792 — intervention group
Group type: COMPARATOR
Intervention: MDMP
Number of subjects: 42
Study 14768792 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 42
Study 10809263 — intervention group
Group type: EXPERIMENTAL
Intervention: High positive end-expiratory pressure (15 cm H2O) with conventional I:E ratio (1:2)
Number of subjects: 22
Study 10809263 — intervention group
Group type: EXPERIMENTAL
Intervention: Low positive end-expiratory pressure (5 cm H2O) with inverse I:E ratio (2:1)
Number of subjects: 22
Study 10809263 — intervention group
Group type: EXPERIMENTAL
Intervention: Low positive end-expiratory pressure (5 cm H2O) with conventional I:E ratio (1:2)
Number of subjects: 22
Study 10809263 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all settings (A, B, C)
Number of subjects: 22
Study 9123923 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumex 5
Number of subjects: 40
Study 9123923 — intervention group
Group type: COMPARATOR
Intervention: 5% normal serum albumin (5% NSA)
Number of subjects: 40
Study 1536439 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (3.0 micrograms/kg.min)
Number of subjects: 44
Study 1536439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (0.5 microgram/kg.min)
Number of subjects: 44
Study 4038511 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous metoclopramide (MCP) at a dose of 2 mg/kg IV for three doses
Number of subjects: 30
Study 4038511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high-dose intravenous metoclopramide (MCP) and intravenous dexamethasone (DXM) at a dose of 20 mg IV for three doses
Number of subjects: 30
Study 31463735 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 23
Study 31463735 — intervention group
Group type: COMPARATOR
Intervention: Guide booklet
Number of subjects: 23
Study 30380988 — intervention group
Group type: EXPERIMENTAL
Intervention: 1120 primer pairs generated from SSR analysis
Number of subjects: 177
Study 30380988 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of selected primer pairs
Number of subjects: 177
Study 27357297 — intervention group
Group type: EXPERIMENTAL
Intervention: Project delivered telephone smoking cessation counselling
Number of subjects: 378
Study 27357297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 378
Study 27357297 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline support
Number of subjects: 378
Study 27357297 — intervention group
Group type: EXPERIMENTAL
Intervention: Project delivered telephone cessation counselling calls
Number of subjects: 378
Study 27357297 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use during counselling calls
Number of subjects: 378
Study 23973522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg once daily for 4 weeks, with possible increase to 8 mg based on investigator discussion.
Number of subjects: 562
Study 23973522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg once daily (with option to decrease to 4 mg).
Number of subjects: 562
Study 23973522 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 562
Study 22180155 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine (PVI) drops
Number of subjects: 242
Study 22180155 — intervention group
Group type: COMPARATOR
Intervention: 1% PVI irrigation (control)
Number of subjects: 242
Study 20099954 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 170
Study 20099954 — intervention group
Group type: COMPARATOR
Intervention: 12-step (TS)
Number of subjects: 170
Study 18588561 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate combination
Number of subjects: 3421
Study 18588561 — intervention group
Group type: COMPARATOR
Intervention: fluticasone propionate
Number of subjects: 3421
Study 15966221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy group (n=7) with novel arterial infusion regimen using cisplatin (CDDP) and 5‐fluorouracil (5‐FU)
Number of subjects: 15
Study 15966221 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=8) with no adjuvant chemotherapy
Number of subjects: 15
Study 15966221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy group (n=7)
Number of subjects: 15
Study 15966221 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 15
Study 11840104 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute sciatica patients (Group IA)
Number of subjects: 128
Study 11840104 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatica patients at 4-year follow-up (Group IB)
Number of subjects: 128
Study 11840104 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing discectomy (Group II)
Number of subjects: 128
Study 10429744 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 0
Study 7773582 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral/intravenous fluconazole (400 mg daily)
Number of subjects: 90
Study 7773582 — intervention group
Group type: COMPARATOR
Intervention: Oral nystatin plus miconazole inhalations
Number of subjects: 90
Study 7773582 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric amphotericin B
Number of subjects: 90
Study 7773582 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic fungal infection
Number of subjects: 90
Study 2275309 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical zinc oxide
Number of subjects: 37
Study 2275309 — intervention group
Group type: COMPARATOR
Intervention: Zinc sulfate at three different concentrations
Number of subjects: 37
Study 2275309 — intervention group
Group type: COMPARATOR
Intervention: Zinc deficiency
Number of subjects: 37
Study 2275309 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide medicated occlusive dressing
Number of subjects: 37
Study 7404497 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) heparin
Number of subjects: 100
Study 7404497 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) heparin
Number of subjects: 100
Study 31521029 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training program (7 sessions)
Number of subjects: 110
Study 31521029 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 110
Study 28820753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular lubricants
Number of subjects: 104
Study 28820753 — intervention group
Group type: COMPARATOR
Intervention: Bandage contact lenses
Number of subjects: 104
Study 28820753 — intervention group
Group type: COMPARATOR
Intervention: Punctal plugs
Number of subjects: 104
Study 24298982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylindrical implant
Number of subjects: 93
Study 24298982 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical/cylindrical implant
Number of subjects: 93
Study 24298982 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study 23477479 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated parenting intervention for ADHD (IPI-A)
Number of subjects: 98
Study 23477479 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral parent training (BPT)
Number of subjects: 98
Study 21368077 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-event multilevel surgery
Number of subjects: 19
Study 21368077 — intervention group
Group type: COMPARATOR
Intervention: Control group (progressive resistance strength training)
Number of subjects: 19
Study 19345510 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg daily) during Detoxification Phase (5-14 days)
Number of subjects: 40
Study 19345510 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg daily) during Rehabilitation Phase (after detoxification)
Number of subjects: 40
Study 19345510 — intervention group
Group type: COMPARATOR
Intervention: Placebo during Detoxification Phase (5-14 days)
Number of subjects: 40
Study 16983476 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic formula (Synbiotic 2000Forte)
Number of subjects: 65
Study 16983476 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 65
Study 15014939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training for 12 weeks
Number of subjects: 26
Study 15014939 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 26
Study 11170991 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of RTS,S/SBAS2
Number of subjects: 64
Study 11170991 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of RTS,S/SBAS2
Number of subjects: 64
Study 11170991 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 standard doses of RTS,S/SBAS2
Number of subjects: 64
Study 11170991 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 one-half doses of RTS,S/SBAS2
Number of subjects: 64
Study 11170991 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 one-fifth doses of RTS,S/SBAS2
Number of subjects: 64
Study 11170991 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 64
Study 9779247 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and systemic medication
Number of subjects: 0
Study 9779247 — intervention group
Group type: COMPARATOR
Intervention: Serum tenascin-C measurement
Number of subjects: 0
Study 8154950 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic consultant
Number of subjects: 482
Study 8154950 — intervention group
Group type: COMPARATOR
Intervention: Physicians' orders
Number of subjects: 482
Study 8154950 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician feedback
Number of subjects: 482
Study 3337344 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (pH, 5.5) 3 mg/kg
Number of subjects: 60
Study 3337344 — intervention group
Group type: COMPARATOR
Intervention: Alkalinized bupivacaine 0.5% (pH, 7.05-7.15) 3 mg/kg
Number of subjects: 60
Study 1347293 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral ECT
Number of subjects: 24
Study 1347293 — intervention group
Group type: EXPERIMENTAL
Intervention: Left unilateral ECT
Number of subjects: 24
Study 1347293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 24
Study 1347293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive pharmacotherapy
Number of subjects: 24
Study 1347293 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover bilateral ECT
Number of subjects: 24
Study 1347293 — intervention group
Group type: COMPARATOR
Intervention: ECT nonresponders
Number of subjects: 24
Study 623041 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (fat 24%, carbohydrate 58%, protein 18% of energy)
Number of subjects: 22
Study 623041 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (fat 47%, carbohydrate 35%, protein 18% of energy)
Number of subjects: 22
Study 31836722 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent dermal matrix
Number of subjects: 10
Study 31836722 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary granulation-tissue-inducing dressing
Number of subjects: 10
Study 31836722 — intervention group
Group type: COMPARATOR
Intervention: No dermal component (Control)
Number of subjects: 10
Study 28233277 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous plasma coating of meshes prior to implantation
Number of subjects: 428
Study 28233277 — intervention group
Group type: COMPARATOR
Intervention: Non-coated meshes
Number of subjects: 428
Study 24448017 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised back and core exercise performed on duty, 2X/week, 24 weeks
Number of subjects: 64
Study 24448017 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=28)
Number of subjects: 64
Study 24392608 — intervention group
Group type: EXPERIMENTAL
Intervention: Folkloric dance program and screen time reduction curriculum
Number of subjects: 83
Study 21725168 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic whole body vibration (WBV) - 5 cycles on three days, each cycle consisting of 5 stimulus trains of 60 seconds duration (frequency 6.5 Hz) with 60 seconds resting time between stimuli.
Number of subjects: 18
Study 21725168 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment - 1 Hz.
Number of subjects: 18
Study 19408036 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (Paractin) tablets, 30% total andrographolides, administered three times a day for 14 weeks
Number of subjects: 60
Study 19408036 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (Paractin) tablets
Number of subjects: 60
Study 17525777 — intervention group
Group type: COMPARATOR
Intervention: Lumbar facet joint nerve blocks using bupivacaine (Control Group I)
Number of subjects: 60
Study 17525777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar facet joint nerve blocks using bupivacaine and Sarapin (Group II)
Number of subjects: 60
Study 17525777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar facet joint nerve blocks using bupivacaine and steroids (Group III)
Number of subjects: 60
Study 17525777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar facet joint nerve blocks using bupivacaine, Sarapin, and steroids (Group IV)
Number of subjects: 60
Study 17525777 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid group (Groups I and II)
Number of subjects: 60